May 19, 2014 11:47 UTC

Research and Markets: PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f6mpbb/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain.

The aging population in Japan is growing at an accelerated rate compared with other countries forecast in this report, accounting for the significant hike in sales during the 10-year forecast, along with low rates of generic substitution. Several products will be launched between 2012 and 2016, with some losing patent life during the same forecast period.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

  • Diagnosis - The UK Brain Bank Criteria
  • Treatment Guidelines and Leading Prescribed Drugs
  • Dopaminergic Therapy Classes
  • Treatment of Parkinson's disease by Stage
  • Parkinson's Disease Assessment Scales
  • Unified Parkinson's Disease Rating Scale (UPDRS)
  • Hoehn and Yahr Clinical Staging
  • Other Clinical Assessments

5 Competitive Assessment

  • Product Profiles - Levodopa Combination Therapy
  • Product Profiles - COMT Inhibitors
  • Dopamine Agonists
  • Product Profiles - Adenosine 2A Inhibitor
  • Product Profiles - Other Therapies

6 Opportunity and Unmet Need

  • Treatment of Motor Complications - Dyskinesias and OFF Episodes
  • Treatment of Non-Motor Symptoms and Dementia
  • Neuroprotective/Disease-Modifying Agents
  • Improved Drug Formulations
  • Identification of Reliable Biomarkers
  • Improved Clinical Trial Design

7 Pipeline Assessment

  • Mavoglurant/AFQ056
  • CD/LD-GR
  • Other Late-Stage Pipeline Products

8 Current and Future Players

  • Merck
  • Roche
  • AbbVie
  • UCB
  • GlaxoSmithKline
  • Novartis
  • Orion
  • Newron
  • Civitas
  • Impax
  • Lundbeck

9 Market Outlook

10 Appendix

For more information visit http://www.researchandmarkets.com/research/f6mpbb/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System


Source: Research and Markets